DexCom, Inc. (DXCM) Q4 2024 Earnings Call Transcript
DexCom, Inc. (NASDAQ:DXCM ) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Sean Christensen - Vice President of Finance and Investor Relations Kevin Sayer - Chairman, President and Chief Executive Officer Jereme Sylvain - Chief Financial Officer Jake Leach - Chief Operating Officer Conference Call Participants Larry Biegelsen - Wells Fargo Jeff Johnson - Baird Robbie Marcus - J.P. Morgan Danielle Antalffy - UBS Travis Steed - Bank of America Joanne Wuensch - Citibank Matt Taylor - Jefferies Matthew O'Brien - Piper Sandler Jayson Bedford - Raymond James Shagun Singh - RBC Capital Markets Chris Pasquale - Nephron Research Steve Lichtman - Oppenheimer Issie Kirby - Redburn-Atlantic Michael Polark - Wolfe Research Patrick Wood - Morgan Stanley Sam Eiber - BTIG Mike Kratky - Leerink Operator Thank you for standing by.
DexCom: Revenue Up, EPS Misses Mark
DexCom (DXCM 0.26%), known for its continuous glucose monitoring (CGM) systems, recently unveiled its Q4 2024 earnings report on Feb. 13, 2025. This release highlighted an 8% growth in revenue, which reached $1.114 billion, slightly exceeding analysts' expectations of $1.112 billion.
Here's What Key Metrics Tell Us About DexCom (DXCM) Q4 Earnings
The headline numbers for DexCom (DXCM) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
DexCom (DXCM) Misses Q4 Earnings Estimates
DexCom (DXCM) came out with quarterly earnings of $0.45 per share, missing the Zacks Consensus Estimate of $0.50 per share. This compares to earnings of $0.50 per share a year ago.
Dexcom beats fourth-quarter sales, reiterates 2025 revenue forecast
Medical device maker Dexcom beat fourth-quarter sales estimates helped by resilient demand for its continuous glucose monitors (CGMs) used by patients with diabetes.
Dexcom Tumbles As Fourth-Quarter Profit Lags Expectations
Dexcom stock fell late Thursday after the company missed fourth-quarter profit expectations by a nickel per share. The post Dexcom Tumbles As Fourth-Quarter Profit Lags Expectations appeared first on Investor's Business Daily.
DXCM Q4 Earnings to Reflect Market Expansion & Stelo Impact?
DexCom Q4 results are likely to reflect strong growth on the back of U.S. sales expansion, global gains and Stelo traction, driving momentum and market expansion into 2025.
Countdown to DexCom (DXCM) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Evaluate the expected performance of DexCom (DXCM) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Should You Buy DexCom Stock Before Feb. 13?
DexCom (DXCM 1.51%) is a healthcare company that makes continuous glucose monitoring (CGM) devices, which help people track glucose levels.
Prediction: This Top Growth Stock Will Outperform the Market in the Next Decade
Medical device specialist DexCom (DXCM -0.90%) has substantially underperformed the market over the trailing-12-month period. The diabetes-focused company disappointed investors last year due to unimpressive financial results, especially in the second and third quarters.
DXCM's Preliminary Results Show Strong Growth: How to Play the Stock?
DexCom Inc. DXCM is off to a strong start in 2025, with its stock rallying 5.7% following the release of its preliminary results for the fourth quarter and fiscal 2024 on Jan. 13, 2025. The company's robust performance has reaffirmed investor confidence, driven by impressive revenue growth and a promising outlook for 2025.
DexCom: Fairly Priced In 2025; Why I'm Not Expecting A Share Price Comeback
DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, with muted enthusiasm from Wall Street today, and a "Hold" rating for me for 2025. I suspect the market overestimated DexCom's mass-market potential, leading to a reality check and a savage bear run on its stock in the past year.
